BridgeBio Pharma, Inc. cotiza a 63.30 USD y tiene una capitalización bursátil de $12.4B. En los últimos 12 meses ha facturado $713M con un margen de flujo de caja libre del -89.0%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR…
| Periodo | 2026-10 | 2026-08 | 2026-05 | 2026-02 |
|---|---|---|---|---|
| Real | — | $-0.78 | $-0.84 | $-0.94 |
| Estimado | $-0.63 | $-0.58 | $-0.62 | $-0.62 |
| Sorpresa | — | -34.5% | -35.5% | -51.6% |
| Métrica | BBIO | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 95.8% | 57.0% | +38.8% |
| Operating Margin | -104.3% | -38.6% | -65.6% |
| Net Margin | -144.4% | -33.6% | -110.8% |
| FCF Margin | -89.0% | -13.9% | -75.2% |
| ROE | — | -40.4% | — |
| ROA | -77.5% | -32.0% | -45.4% |
| Current Ratio | 2.77 | 2.84 | -0.07 |
| Debt / Equity | -0.96 | 0.28 | -1.24 |